ClinicalTrials.gg
CompletedNCT06566885ELBRUSUpdated Nov 12, 2026

Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia

An observational study in Severe Asthma, sponsored by AstraZeneca. Completed at 15 sites in Russia. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by AstraZeneca · Observational

How we know

Updated Nov 12, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
125
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
96th of 110
125 · median 500
Started
2024
with 25 others
Observational
111 of 359
9 open now
Registered
327th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 96th largest by enrollment of the 110 observational ones that give a count, is one of 26 that started in 2024, is one of 111 observational ones, and was the 327th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

ELBRUS is a 12-month (52-week), multi-centre, prospective, non-comparative and non-interventional (observational), post-reimbursement real-world evidence study that will assess patient-reported outcomes after tezepelumab treatment initiation in participants with severe asthma in Russia.

Read the detailed description

This is a multi-centre, retrospective-prospective, non-comparative and non-interventional (observational) cohort study involving primary and secondary data collection within real-world settings of participants who initiate tezepelumab for treatment of severe uncontrolled asthma. Participants of the study will be the patients eligible for tezepelumab treatment based on the assessment in accordance with the approved product Summary of Product Characteristics (SmPC) in Russia. The administration of tezepelumab will be independent of this study (i.e., a decision of tezepelumab initiation is based on the physician's choice and regulatory and clinical features, not on recruitment/participation in the study). Tezepelumab is indicated as an add-on maintenance treatment for severe asthma, therefore, patients will continue background asthma therapy throughout the study, irrespective of their decision to participate in this study or not.

Approximately 110 eligible participants of both sexes, aged 12 years or older will be treated with tezepelumab available in the market and according to the Russian reimbursement policies in approximately 20 sites. In eligible participants who agree to take part in the study, the enrolment date is defined as the date of informed consent or assent. After enrolment and evaluation of inclusion/exclusion criteria, study participants will commence tezepelumab treatment as per the physician's decision and following the local product SmPC. The index date is defined as the date when participants have received the first dose of tezepelumab. The enrolment period is the period between enrolment date and index date. Additionally, participants may be enrolled in this study up to 4 weeks after the first dose of tezepelumab, but no longer, to avoid responder bias.

Participants will be followed for a maximum period of 52 weeks after index date, irrespective of treatment discontinuation. Patient-reported outcomes - the primary endpoint (ACQ-5) and SNOT-22 will be retrospectively collected during enrolment for all patients (i.e. the most recent available values in the 52 weeks prior to index date), and prospectively collected at suggested visits at Weeks 4, 12, 24, and 52 following index date. For patients who initiate treatment after being enrolled into the study the baseline value may be collected prospectively after enrolment before start of treatment.

The baseline period is defined as the 52 weeks prior to the index date. Outcomes of interest, such as severe asthma exacerbations, medication use, and healthcare resource utilization, will be collected during enrolment retrospectively for the baseline period (52 weeks prior to the index date) and then prospectively at Weeks 4, 12, 24, and 52 following index date.

Overall expected duration of the study (from the first patient inclusion to the last patient last visit) is about 2 years or until 110 eligible patients are included to the study and data on these patients are collected, whichever occurs first.

As an observational, this study does not imply any intervention into a routine clinical practice, including choice of treatment modality or additional diagnostic methods.

03

Conditions studied

  • Severe Asthma

Browse trials for

Keywords

  • tezepelumab
  • severe asthma
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants of both sexes, aged 12 years or older with severe uncontrolled asthma despite medium or high doses of ICS, who have commenced/will commence treatment with tezepelumab as determined by their routine clinical care.

The study population is planned to comprise approximately 110 participants in approximately 20 sites. Eligible patients will be enrolled consecutively at each site to minimize selection bias at each site

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

be eligible for enrolment into this study if all of the following criteria are met:

  1. Male or female participants aged 12 years or older at the time of signing the ICF or assent.
  2. Prescribed and initiated treatment with tezepelumab according to SmPC and local market reimbursement criteria. A period between treatment initiation and enrolment should be no more than 4 weeks.
  3. Diagnosis of asthma established for at least 52 weeks prior to tezepelumab initiation and symptoms confirmed by the Investigator not to be due to alternative diagnoses.
  4. Received at least one prescription of medium or high doses of ICS during the 52 weeks prior to tezepelumab initiation, with medium or high doses of ICS defined according to the GINA 2022 (see below Note #1).
  5. Use of additional asthma maintenance controller medication(s) in addition to ICS (e.g., LABA, leukotriene receptor inhibitors, theophylline, LAMA, and cromones) for at least 52 weeks prior to tezepelumab initiation. The additional maintenance controller medication may be contained in a combination product (e.g., ICS/LABA).
  6. Documented history of at least 2 severe asthma exacerbations during the 52 weeks prior to tezepelumab initiation. For participants receiving prior biologic drugs for ≥ 8 months, at least 1 severe exacerbation must have occurred on prior biologic treatment. Participants are excluded if, in the opinion of the Investigator, prior biologic treatment had provided significant clinical benefit in the past 52 weeks, despite the participant experiencing ≥ 2 severe exacerbations during 52 weeks prior to tezepelumab initiation.
  7. Individuals with ACQ-5 score ≥ 1.5 (indicating inadequate asthma symptom control) at enrolment or up to 12 weeks before enrolment.
  8. Currently receive care from specialist physicians (e.g., pulmonologists and/or allergists) at the Investigator's or sub-Investigator's site.
  9. Provision of signed and dated written , including assent (informed consent for participants under 18 years old).
  10. Participants are able to read, understand and complete the questionnaires required by the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Any to tezepelumab as per the approved product SmPC in Russia or in the opinion of the Investigator.
  2. Administration of concurrent biologic drug for asthma since the index date, except for stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment). Enrolment of patients who were switched from other biologic(s) to tezepelumab is allowed, and an acceptable timeframe since the last prior asthma biologic drug is ≥ 30 days. The number of participants with prior biologic treatment (switching to tezepelumab) should be targeted at 20% or less.
  3. Participation in an observational study that might, in the Investigator's opinion, influence the assessment for the current study, or participation in an interventional clinical trial in the last 3 months.
  4. Pregnancy or lactation period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
125 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in ACQ-5 score from baseline

    time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation. Each question of the Asthma Control Questionnaire-5 is ranged on a 7-point scale from 0 (no impairment) to 6 (maximum impairment). The questions are equally weighted and the ACQ score is the mean of the all questions. The total score of ≥1.5 indicates a high probability that asthma is "poorly controlled", 0-0.75 - that asthma is "well controlled", and 0.75-1.5 is a "grey zone".

    Time frame: 1 year

Secondary outcomes

  1. 1. ACQ-5 score at different points of time

    time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation. Each question of the Asthma Control Questionnaire-5 is ranged on a 7-point scale from 0 (no impairment) to 6 (maximum impairment). The questions are equally weighted and the ACQ score is the mean of the all questions. The total score of ≥1.5 indicates a high probability that asthma is "poorly controlled", 0-0.75 - that asthma is "well controlled", and 0.75-1.5 is a "grey zone".

    Time frame: 1 year

  2. 2. Proportion of participants with well-controlled asthma

    (ACQ-5 score ≤ 0.75) overall during the study and at different points of time \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]

    Time frame: 1 year

  3. 3. Proportion of participants with ACQ-5 response

    (reduction of ≥ 0.5 in score from baseline) overall during the study and at different points of time \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]

    Time frame: 1 year

  4. 4. Median time to ACQ-5 response

    (reduction of ≥ 0.5 in score from baseline), weeks \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following

    Time frame: 1 year

  5. 8. Pre- and post-bronchodilator forced expiratory volume in 1 second

    (FEV1) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]

    Time frame: 2 years

  6. 9. Pre- and post-bronchodilator forced vital capacity

    (FVC) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]

    Time frame: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation

  7. 10. Pre-bronchodilator forced expiratory flow

    (FEF) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]

    Time frame: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation

  8. 11. Changes on pre- and post-bronchodilator FEV1 from baseline

    time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation. Forced expiratory volume in 1 second (FEV1) response is defined as achievement of either a ≥ 5% or ≥ 100 mL improvement from baseline

    Time frame: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation

  9. 12. Proportion of pre- and post-bronchodilator FEV1 responders

    (defined as participants who achieved either a ≥ 5% or ≥ 100 mL improvement from baseline) overall during the study and at different points of time \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\];

    Time frame: 1 year

  10. 13. FRC

    Functional residual capacity (FRC) evaluated by spirometry and/or body plethysmography (if available) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]. Units of measurement: % predicted and L.

    Time frame: 1 year

  11. 14. Annualised rate of severe asthma exacerbations

    \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]

    Time frame: 2 years

  12. 15. Proportion of participants with reduced total number of severe asthma exacerbations at Week 52 following tezepelumab initiation compared with baseline

    \[time points to measure: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]: a. Proportion of participants with any reduction in severe exacerbations number;

    Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation

  13. 16. Change in annualised rate of severe asthma exacerbations from the baseline period to the follow-up period after tezepelumab initiation

    \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]

    Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation

  14. 17. Proportion of participants with 0, 1, 2, ≥3 severe asthma exacerbations

    \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]

    Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation

  15. 18. Cumulative days of severe asthma exacerbations

    (calculated in participants who had severe asthma exacerbations at baseline) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]

    Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation

  16. 19. Proportion of participants with any SCS use

    ('systemic' means oral, parenteral CS) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]

    Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation

  17. 20. Proportion of participants with any reduction (≥ 25%, ≥ 50%, ≥ 75%, and 100% reduction) from baseline on cumulative SCS dose

    (in prednisone equivalent dose) (to be calculated in participants with SCS use at baseline) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]

    Time frame: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation

  18. 21. Change in median SCS dose from baseline

    (to be calculated in participants with SCS use at baseline) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]

    Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation

  19. 22. Proportion of participants with long-term (>30 consecutive days) SCS use

    (to be calculated in participants with SCS use at baseline) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]

    Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation

  20. 23. Number (proportion) of participants with asthma-related healthcare resource utilisation

    (by each type) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]

    Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation

  21. 24. Annualised rates of asthma-related hospitalisation, emergency calls (or emergency department visits), and unscheduled out-patient visits to a physician

    \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\];

    Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation

  22. 25. Annualised rates of asthma-related scheduled physician visits or healthcare calls for asthma

    \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]

    Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation

  23. 26. Median overall duration (days) of asthma-related hospitalisations

    \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\].

    Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation

  24. 27. Mean and median duration (days) of treatment with tezepelumab

    to be calculated in all enrolled participants

    Time frame: Week 52

  25. 28. Median time (days) to tezepelumab discontinuation

    to be calculated in participants who discontinued tezepelumab earlier than Week 52 by any reason

    Time frame: Week 52

  26. 29. Proportion of participants discontinued tezepelumab and switched to other biologic drug for asthma treatment and reason(s)

    Time frame: Week 52

  27. 8.2 Changes on pre- and post-bronchodilator FVC from baseline

    Forced Vital Capacity (FVC) (L): both pre-bronchodilator and post-bronchodilator should be recorded. time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation

    Time frame: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation

  28. 8.3 Changes on pre-bronchodilator FEF from baseline

    Pre-bronchodilator forced expiratory flow (FEF) 25-75 - the mean speed of flow during forced expiration of from 25% to 75% of the FVC. Measured in L/sec. time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation

    Time frame: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation

  29. 12.b Proportion of participants with reduced total number of severe asthma exacerbations at Week 52 following tezepelumab initiation compared with baseline

    \[time points to measure: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]: Proportion of participants with at least 50% reduction in severe exacerbations number;

    Time frame: up to 2 years

  30. 12.c Proportion of participants with reduced total number of severe asthma exacerbations at Week 52 following tezepelumab initiation compared with baseline

    \[time points to measure: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]: c. Proportion of participants who completed 52 weeks of tezepelumab treatment without any severe asthma exacerbation

    Time frame: 2 years

  31. 10.2 RLV

    Residual lung volume (RLV) evaluated by spirometry and/or body plethysmography (if available) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]. Units of measurement: % predicted and L.

    Time frame: 1 year

  32. 10.3 TLC

    Total lung capacity (TLC) evaluated by spirometry and/or body plethysmography (if available) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]. Units of measurement: % predicted and L.

    Time frame: 1 year

  33. 5. SNOT-22 questionnaire score

    5\. SNOT-22 questionnaire score in patients with comorbid chronic rhinosinusitis with nasal polyps (rhinosinusitis polyposis) at different points of time

    Time frame: baseline and at Weeks 4, 12, 24, and 52 following tezepelumab initiation

  34. 6. Proportion of participants with clinically meaningful improvement

    Proportion of participants with clinically meaningful improvement (reduction in SNOT-22 score by ≥ 8.9) overall during the study and at different points of time

    Time frame: baseline and at Weeks 4, 12, 24, and 52 following tezepelumab initiation

  35. 7. Median time to SNOT-22 response

    Median time to SNOT-22 response (reduction of ≥8.9 in score from baseline), weeks \[time points to measure

    Time frame: baseline and at Weeks 4, 12, 24, and 52 following tezepelumab initiation

Other outcomes

  1. 1. Median time from index date to lung function response by FEV1

    (FEV1 response is defined as achievement of either a ≥ 5% or ≥ 100 mL improvement from baseline) \[time points to measure: baseline and at Weeks 12, 24 and 52 following tezepelumab initiation\]

    Time frame: 1 year

  2. 2. Proportion of participants with sustained (12 weeks or longer) response by FEV1

    \[time points to measure: baseline and at Weeks 12, 24 and 52 following tezepelumab initiation\]

    Time frame: 1 year

  3. 3. Median time from index date to spirometry and/or body plethysmography response

    (spirometry and/or body plethysmography response is defined as achievement of a ≥ 5% improvement from baseline) \[time points to measure: baseline and at Weeks 12, 24 and 52 following tezepelumab initiation\];

    Time frame: 1 year

  4. 4. Proportion of participants with sustained (12 weeks or longer) spirometry and/or body plethysmography response

    \[time points to measure: baseline and at Weeks 12, 24 and 52 following tezepelumab initiation\]

    Time frame: 1 year

  5. 5. Proportion of participants with medications for asthma treatment by drug class

    \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]

    Time frame: 2 years

  6. 6. Cumulative dose of ICS by each ICS medication

    (ICS may be contained in a single-component product and a combination product, e.g., ICS/LABA) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]

    Time frame: 2 years

  7. 7. Medication possession ratio (MPR)

    total days' supply of a medication in a particular time period, divided by the number of days in the time period

    Time frame: Week 52

  8. 8. A patient's body weight (kg) measured in participants with elevated BMI at enrolment

    (≥25 mg/m2) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\];

    Time frame: 1 year

  9. 9. Change in body weight from baseline calculated in participants with elevated BMI at enrolment

    (≥25 mg/m2) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\].

    Time frame: 1 year

  10. 10. Number and proportion of participants who achieved asthma clinical remission at Week 52

    Time frame: Week 52

  11. 1.2 Median duration of lung function response by FEV1 from index date

    time points to measure: baseline and at Weeks 12, 24 and 52 following tezepelumab initiation

    Time frame: 1 year

  12. 3.2 Median duration of spirometry and/or body plethysmography response from index date (if available)

    (spirometry and/or body plethysmography response is defined as achievement of a ≥ 5% improvement from baseline) \[time points to measure: baseline and at Weeks 12, 24 and 52 following tezepelumab initiation\];

    Time frame: 1 year

  13. Number and proportion of patients with chronic rhinosinusitis with nasal polyps (CRSwNP)

    Number and proportion of patients with chronic rhinosinusitis with nasal polyps (CRSwNP); * Number and proportion of patients with chronic rhinosinusitis without nasal polyps; * Number and proportion of patients with CRSwNP with different levels of eosinophils blood count: * \<150 cells/μl; * ≥150 cells/μl; * ≥300 cells/μl.

    Time frame: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation

  14. Number and proportion of patients with CRSwNP and presence of biologic therapy prior to tezepelumab initiationor

    Number and proportion of patients with CRSwNP and presence of biologic therapy prior to tezepelumab initiationor

    Time frame: 1 year

07

Study locations

15 sites
  • Research Site
    Kaliningrad, Russia
  • Research Site
    Kemerovo, Russia
  • Research Site
    Krasnodar, Russia
  • Research Site
    Moscow, Russia
  • Research Site
    Nal'chik, Russia
  • Research Site
    Nizhny Novgorod, Russia
  • Research Site
    Novosibirsk, Russia
  • Research Site
    Orenburg, Russia
  • Research Site
    Petrozavodsk, Russia
  • Research Site
    Saint Petersburg, Russia
  • Research Site
    Shelehov, Russia
  • Research Site
    Stavropol, Russia
  • Research Site
    Tomsk, Russia
  • Research Site
    Ulan-Ude, Russia
  • Research Site
    Yekaterinburg, Russia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Oct 2026, 25 months.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's 25 months is close to that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2024
First posted
Aug 22, 2024
StartActual
Sep 10, 2024
Primary completionActual
Oct 20, 2026was Sep 2026
CompletionActual
Oct 20, 2026was Sep 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 12, 2026
Primary completion
Sep 30, 2026→Oct 20, 2026 (actual)
Nov 12, 2026
Study completion
Sep 30, 2026→Oct 20, 2026 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Active, not recruiting→Completed
    Primary completion Sep 30, 2026→Oct 20, 2026 (now actual)
    Study completion Sep 30, 2026→Oct 20, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06566885
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 22, 2024
Start date
Sep 10, 2024
Primary completion
Oct 20, 2026
Completion
Oct 20, 2026
Last update
Nov 12, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion